Purpose Vitiligo-like depigmentation in patients with melanoma may be associated with more
favorable clinical outcome. We conducted a systematic review of patients with stage III to IV …

Background Many patients with moderate-to-severe atopic dermatitis (AD) require systemic
immunomodulating treatment to achieve adequate disease control. Objective We sought to …

The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing
evidence-based treatment. The global Harmonising Outcome Measures for Eczema (HOME) …

Background Methotrexate and cyclosporine are well-known systemic therapies for moderate-to-severe
chronic plaque psoriasis. We conduced a randomized, controlled trial comparing …

This is an executive summary of all consented recommendations of the European Psoriasis
Guidelines–Update 2015. The long version of this guideline is available online as …

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women.
Initial signs of androgenetic alopecia usually develop during teenage years leading to …

Innate lymphoid cells (ILCs) are increasingly appreciated as important regulators of tissue
homeostasis and inflammation. However, their role in human skin remains obscure. We found …

BACKGROUND: Patients with severe atopic eczema frequently require systemic treatment
to control their disease. Methotrexate and azathioprine are proposed as off-label treatment …

This evidence‐ and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

A large number of clinical measures of psoriasis are used in clinical trials and daily practice.
These measures lack uniformity and validation. However, valid outcome and severity …